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Summary Levetiracetam is highly effective as add-on treatment in refractory partial-
onset seizures but there are only limited data supporting its beneﬁt in generalised
epilepsies. We have reviewed the clinical records of 25 consecutive adult patients
with generalised epilepsies (84% females; mean age 34 (range 16—75) years) pre-
scribed levetiracetam for at least six months. The epilepsy was considered idiopathic
in 22 patients (88%)–—including 13 with juvenile myoclonic epilepsy–—and symptomatic
in three. Most patients (68%) reported some improvement in seizure frequency on lev-
etiracetam including 16% who became seizure free. Levetiracetam was generally well
tolerated although 11/25 (44%) of patients reported some tiredness, weight change
or rash. Levetiracetam was stopped in ﬁve patients, four because of side effects and
one though lack of efﬁcacy. In four cases, pre-existing antiepileptic medication was
withdrawn, leaving levetiracetam as monotherapy. We conclude that levetiracetam
is a useful add-on treatment for patients with refractory generalised epilepsies.
© 2003 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
Introduction
Levetiracetam (ucb L059) [Keppra] is a second-
generation antiepileptic drug (AED) shown to be
highly effective in the management of partial-onset
seizures, and well tolerated compared to other new
AEDs.1 It is an S-enantiomer pyrrolidine derivative,
ﬁrst investigated in the 1980s for its cognitive en-
hancing and anxiolytic effects.2 Its antiepileptic
properties were noted later, and animal studies
have shown a broad spectrum of antiepileptic ef-
fect in both partial onset and primarily generalised
epilepsies.3, 4
Since its launch in 2000, levetiracetam has be-
come established as an add-on therapy in the man-
agement of partial-onset seizures in adults. There
*Corresponding author. Tel.: +44-29-207-42834;
fax: +44-29-207-66144.
E-mail address: SmithPE@cardiff.ac.uk (P.E.M. Smith).
is anecdotal evidence of its effectiveness also in
human primarily generalised epilepsies, including
those manifesting myoclonic seizures.5 We have
therefore occasionally used levetiracetam outside
its current product licence as an add-on AED in
patients with resistant generalised epilepsies, and
here we report our preliminary experience.
Patients and methods
In December 2002, we identiﬁed and reviewed the
clinical records of consecutive patients with gener-
alised epilepsies attending our epilepsy unit where
levetiracetam had been previously prescribed as
add-on therapy between December 2000 and May
2002. Thus all patients included in the study had
been prescribed levetiracetam at least six months
before the review date. The seizure frequency
over the six months preceding the prescription of
1059-1311/$30 — see front matter © 2003 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.seizure.2003.06.001
476 S.P. Kumar, P.E.M. Smith
levetiracetam was noted and the clinical response
to levetiracetam over the following period of at
least six months was divided into the following
categories:
• Seizure free: No seizures for at least six months.
• Marked improvement: Seizure frequency reduced
to 20% of baseline at six months.
• Moderate improvement: Seizure frequency re-
duced to 20—50% of baseline at six months.
• Mild improvement: Seizure frequency still above
50% of baseline but improvement in well being
reported.
• No improvement: Seizure frequency still above
50% of baseline, but no improvement in well being
reported; treatment still continued.
• Treatment stopped: Levetiracetam either inef-
fective or poorly tolerated.
Results
Twenty-ﬁve patients diagnosed with generalised
epilepsies were identiﬁed from our database who
had been prescribed levetiracetam for at least
six months before December 2002. One additional
patient with unclassiﬁed epilepsy had been erro-
neously categorised as generalised epilepsy and so
was excluded. The case notes of all 25 patients
[4 males (16%) and 21 females (84%), mean age
34.4± 16.6 years (range, 16—75 years)] were avail-
able for review.
Twenty-two of the 25 patients (88%) had idio-
pathic generalised epilepsies (IGE). The sub-types
of IGE were as follows: unspeciﬁed IGE (n = 6),
juvenile myoclonic epilepsy (n = 13), epilepsy
with generalised tonic—clonic seizures on awak-
ening (n = 1), eyelid myoclonia with absences
(n = 1), and peri-oral myoclonia with absences
(n = 1). Three patients had symptomatic gener-
alised epilepsies: progressive myoclonus epilepsy
Table 1 Seizure frequency changes in the 25 patients with generalised epilepsies prescribed levetiracetam for
at least six months.
Response to medication All generalised
epilepsy (n = 25)
Juvenile myoclonic
epilepsy (n = 13)
Other generalised
epilepsies (n = 12)
Seizure free 4 2 2
Marked improvement 4 2 2
Moderate improvement 5 2 3
Mild improvement 4 3 1
No improvement 3 0 3
Discontinued 5 4 1
Deﬁnitions of responses to medication given in text.
(n = 1), generalised epilepsy with severe learn-
ing disability (n = 1), and migraine and epilepsy
overlap syndrome (migralepsy) (n = 1).
The dosing schedule in our patients was generally
slower than that recommended by manufacturer.6
Our usual starting dose was 250mg daily for one
week, increased by 250mg weekly or two weekly
towards a usual maintenance dose of 1000—2000mg
daily. The mean duration of levetiracetam pre-
scription was 14.4 months (range 7—26), and the
mean maximum prescribed dose was 1.96 g (range
0.5—3.5 g) daily. The pre-existing AEDs prescribed
as monotherapy were sodium valproate n = 14
(56%), lamotrigine n = 4 (16%) and carbamazepine
n = 1 (4%). Six patients were prescribed two or
more AEDs in various combinations. In four pa-
tients (valproate n = 3, carbamazepine n = 1), the
pre-existing AED was withdrawn to leave levetirac-
etam monotherapy.
The clinical responses to levetiracetam are given
in Table 1. Four of the 25 patients (16%) reported
becoming seizure free on levetiracetam, with some
improvement reported in 17/25 (68%). The seizure
response to levetiracetam was similar in those with
juvenile myoclonic epilepsy and those with other
types of generalised epilepsies. Levetiracetam was
stopped in ﬁve (20%) patients, four because of ad-
verse side effects and one through lack of efﬁcacy.
Eleven (44%) patients reported signiﬁcant side
effects whilst on levetiracetam. Four reported
tiredness, leading one patient to stop the drug. Two
reported weight gain and two reported rash, but in
each case levetiracetam was continued. Other mi-
nor symptoms included bad taste (n = 1), anorexia
(n = 1) and dizziness (n = 1).
Discussion
Levetiracetam was effective as add-on treatment
in these patients with generalised epilepsies. The
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large majority (84%) reported some sustained im-
provement in seizure frequency, and four of the 25
(16%) became seizure free. Furthermore, the re-
tention rate of levetiracetam in these patients was
80% at six months; only one of the four patients
who stopped the medication did so though lack of
efﬁcacy. The response to levetiracetam was no dif-
ferent in patients with juvenile myoclonic epilepsy
than in the remaining patients with other forms of
generalised epilepsy.
This study has two important limitations. Firstly,
it is a retrospective observational study and there-
fore reliant upon documentation of clinical fea-
tures, seizure control and medication side effects
in case notes of variable detail and quality. Sec-
ondly, the number of patients studied was small,
and particularly so given the heterogeneous nature
of the generalised epilepsies, the variety of base-
line treatments, and the varied dosing schedules of
levetiracetam. Nevertheless, these preliminary re-
sults do demonstrate that levetiracetam was useful
as add-on treatment, even in these patients with
resistant generalised epilepsies, with a relatively
high rate of seizure freedom and a high rate of
medication retention after at least six months of
treatment.
There are limited previous data on the use of lev-
etiracetam in generalised epilepsies, used either as
add-on or ﬁrst line treatment. Related pyrrolidone
derivatives are known to be effective in primarily
generalised epilepsies.7 However, previous studies
suggesting a potential role for levetiracetam in the
management of patients with generalised epilep-
sies have been limited to case reports and uncon-
trolled and non-randomised data from small series
as yet published only in abstract form.8, 9 However,
a larger randomised study using levetiracetam in
two oral regimens in a heterogeneous epilepsy
population did demonstrate clear improvements
in seizure control in both generalised and focal
epilepsies.10
The relatively high retention rate among our
patients (80% at six months) is partly attributable
to avoidance of unnecessary dose-related side ef-
fects through a slow introduction of levetiracetam
in these patients compared to the manufacturer’s
recommendation.6 The majority of females in the
study group was surprising but does not appear to
reﬂect selection bias; indeed, we recognise the
potential problems in prescribing a novel medica-
tion to women of childbearing potential given the
current paucity of safety data on levetiracetam
in human pregnancy. In practice, we should ad-
vocate withholding levetiracetam from women of
childbearing potential unless safer alternatives are
either inappropriate or ineffective.
In conclusion, levetiracetam appears to be a use-
ful add-on treatment in patients with resistant gen-
eralised epilepsies. Randomised controlled trials
are needed to deﬁne its role as a second and even
as ﬁrst line monotherapy in generalised epilepsy.
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